- Published at
- by seekingalpha.com
positive
positive
Healing Numbers, Hurting Valuation: Bioventus’ Mixed Bag In Q2 2024 (NASDAQ:BVS)
Bioventus sees revenue rise in Q2 with strong sales forecast for orthobiologics products. Click here to read an analysis of BVS stock now.